Acemannan, an acetylated polymannose from Aloe vera, has immunomodulatory effects. Acemannan induces IL-6/-8 expression, and p50/DNA binding in gingival fibroblasts, at least partly, via a TLR5/NF-κB-dependent signaling pathway. Acemannan selectively binds with TLR5 ectodomain flagellin recognition sites. Acemannan has various medicinal properties like osteogenic, anti-inflammatory, and antibacterial, which accelerate healing of lesions. Also, acemannan is known to have antiviral and antitumor activities in vivo through activation of immune responses. It was concluded that Aloe vera has immense potential as a therapeutic agent. Acemannan induces tissue repair. Acemannan promoted skin wound healing partly through activating AKT/mTOR-mediated protein translation mechanism, which may represent an alternative therapy approach for cutaneous wound. Many research groups have demonstrated the role of
acemannan in dentistry. Acemannan can be used for the treatment of oral aphthous ulceration in patients who wish to avoid the use of steroid medication. Acemannan is an effective natural bioactive substance that promotes bone
growth, increases bone surface, bone volume and bone density.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Acemannan increases NF-κB/DNA binding and IL-6/-8 expression by selectively binding Toll-like receptor-5 in human gingival fibroblasts. | 2017 Apr 1 |
|
Stimulation of Dentin Regeneration by Using Acemannan in Teeth with Lipopolysaccharide-induced Pulp Inflammation. | 2017 Jul |
|
Acemannan and Fructans from Aloe vera (Aloe barbadensis Miller) Plants as Novel Prebiotics. | 2017 Nov 22 |
|
Extraction, Purification, Structural Characteristics, Biological Activities and Pharmacological Applications of Acemannan, a Polysaccharide from Aloe vera: A Review. | 2019 Apr 19 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23240939
A skin patch test was performed on 100 healthy subjects, and 0.5% acemannan in Carbopol® 934P NF (Lubrizol Corporation, USA) was applied to the oral mucosa of the lower lip of 50 healthy participants 3 times/day for 7 days. Another 180 subjects with recurrent aphthous ulceration randomly received one of three treatments: 0.1% triamcinolone acetonide (HOE Pharmaceuticals, Malaysia), 0.5% acemannan in Carbopol® 934P NF, or pure Carbopol® 934P NF. Medications were applied to the ulcers 3 times/day for 7 days.
Route of Administration:
Dental
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/31010204
Acemannan was found to possess oral wound healing functions in human gingival fibroblasts
and rats, including stimulating the expression of keratinocyte growth factor‐1 (KGF‐1), vascular
endothelial growth factor (VEGF) and type I collagen production in cells at a dose of 16 mg/mL
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
110042-95-0
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
DTXSID00149125
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
UZ29E6L2X8
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
6355
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
Z-37
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
C058414
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
m1297
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
Acemannan
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
1426875
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB33378
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
2985
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
C169758
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
UZ29E6L2X8
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106045
Created by
admin on Fri Dec 15 19:46:17 GMT 2023 , Edited by admin on Fri Dec 15 19:46:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY